ABSTRACT: Since early 2020, disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic, causing millions of infections and deaths worldwide. Despite rapid deployment of effective vaccines, it is apparent that the global community lacks multipronged interventions to combat viral infection and disease. A major limitation is the paucity of antiviral drug options representing diverse molecular scaffolds and mechanisms of action. Here we report the antiviral activities of three distinct marine natural products—homofascaplysin A (1), (+)-aureol (2), and bromophycolide A (3)—evidenced by their ability to inhibit SARS-CoV-2 replication at concentrations that are nontoxic toward human airway epithelial cells. These compounds stand as promising candidates for further exploration toward the discovery of novel drug leads against SARS-CoV-2.

COVID-19, caused by infection with the SARS-CoV-2 coronavirus, is a novel disease affecting human populations worldwide that has led to over 5.9 million deaths and 440 million infections as of March 2022. As the pandemic continues, the deployment of several safe and effective vaccines has brought some optimism. Nevertheless, the only FDA-approved direct-acting small-molecule antiviral drugs for SARS-CoV-2 are remdesivir, molnupiravir, and a combination therapy using PF-07321332 with ritonavir (Paxlovid). Remdesivir has been shown to shorten the recovery time in hospitalized patients, whereas molnupiravir significantly reduces the risk of hospitalization and death. The combination therapy using PF-07321332 with ritonavir has displayed promise in phase 2/3 clinical trials, reducing the risk of hospitalization by almost 89% and with no deaths. While these developments are promising, controlling virus transmission and treating patients require development of additional therapeutics, including small-molecule drug candidates that can be used in combination regimens, a therapeutic approach that has proved beneficial in the fight against human immunodeficiency virus, hepatitis B, and hepatitis C virus. Furthermore, there is the possibility of additional benefits to human health through the discovery of compounds with activity against other coronaviruses. Although morbidity caused by many coronaviruses is mild (coronaviruses cause 10–30% of “common cold” upper respiratory tract infections), SARS-CoV-2 is the third highly virulent coronavirus to emerge in the last 20 years, and it is unlikely to be the last. In the search for novel drug candidates to treat or prevent COVID-19, a broad assessment of antiviral activities attributed to known marine and terrestrial natural products is a useful starting point for prioritizing screening of compounds against SARS-CoV-2. A wide array of molecules from terrestrial and marine sources show antiviral activity including inhibition of coronaviruses (Figures S1 and S2). Some of their putative mechanisms of action include the inhibition of the viral spike protein (S) and angiotensin converting enzyme 2 (ACE2) by anthraquinones and tannins (Figure S1, A), inhibition of viral helicase by flavonoids (Figure S1, B), and inhibitory activity against the SARS-CoV chymotrypsin-like protease (3CLpro)/main protease (Mpro) and papain-like cysteine protease (PLpro) by alkaloids, flavonoids, and coumarins (Figure S1, C/D).

Most relevant, recent reports have demonstrated potent in vitro anti-SARS-CoV-2 activity for natural product representatives of isoprenoid, peptide, polyketide, binaphthoquinone, and polyphenol structural classes (Figure 1, B). Recently, the repurposed drug plitidepsin (4, also known as dehydrodideamin B, a depsipeptide from the marine ascidian Aplidium albicans; Figure 1, B) was shown to be more than 20 times as potent as remdesivir against SARS-CoV-2. Taken together, the molecular diversity represented by natural products holds promise for discovery of novel drug leads to fill
Figure 1. (A) Homofascaplysin A (1), (+)-aureol (2), and bromophycolide A (3), which exhibited anti-SARS-CoV-2 activity in the current study. (B) Natural products recently reported to show potent activity against SARS-CoV-2.24−28

Figure 2. Natural products screened with a SARS-CoV-2 live virus assay in the present study, in addition to those in Figure 1, A).
the critical need for SARS-CoV-2 and other RNA viruses of pandemic concern.

### RESULTS AND DISCUSSION

We initiated a study of marine natural products from our collection of several thousand marine extract fractions and pure compounds assembled through the National Institutes of Health (NIH) funded International Cooperative Biodiversity Groups (ICBG) program in Fiji and the Solomon Islands starting in 2004. Natural products with structural similarity to known antiviral molecules, especially those with established activity against coronaviruses and other RNA viruses, were prioritized. Homofascaplysin A (1) was chosen due to previously reported activity of other β-carboline alkaloids against RNA viruses including HIV and dengue virus.\(^\text{29–31}\) Additionally, members of the fasicaplysin class (which includes 1) structurally resemble tryptanthrin (Figure S1, D), an indole quinazoline alkaloid active against human coronavirus NL63.\(^\text{19}\) (+)-Aureol (2) was selected due to its reported anti-influenza activity and because it embodies the sesquiterpene hydroquinone structural class.\(^\text{32}\) Moreover, a close structural analogue, stachylin (16), has shown nanomolar activity against influenza A virus subtype H1N1, further motivating us to prioritize sesquiterpene hydroquinones (Figure S2).\(^\text{33,34}\) Bromophycolide A (3), an unusual meroditerpene macrolide, was selected based on its known anti-HIV activity (Figure 1, A).\(^\text{35}\) Two other biosynthetically related polycyclic analogues, bromophycoic acid B (9) and callophycoic acid B (10), were chosen as additional representatives of this natural product family.\(^\text{36,37}\) Likewise, the complex alkaloid haliconacyclamine A (11) was considered based on its reported anti-HIV activity.\(^\text{38}\) Finally, peyssonnoside A (12) and formoside (13), representative of terpene glycosides, and cladophorol A (14) and cladophorol G (15), representing polyphenols, were also chosen, as compounds from these classes have shown activity against human coronavirus 229E, respiratory syncytial virus, influenza A virus, SARS-CoV PL\(^\text{380}\) and 3CL\(^\text{380}\) enzyme (Figures S1 and S2).\(^\text{20,39,40}\) Thus, 10 unique molecules belonging to five distinct structural classes were selected and purified from our extract library for screening in a SARS-CoV-2 specific assay with live virus in a BSL-3 facility.

Among the 10 natural products that were evaluated, three stood out for their promise based on a series of experiments with SARS-CoV-2-infected human lung cancer Calu-3 cells: homofascaplysin A (1), (+)-aureol (2), and bromophycolide A (3). These three natural products significantly suppressed viral infection while not killing human lung cells, relative to DMSO as control, at 0.5–1 µM (Figure 3). Follow-up experiments (with the same assay conditions) to further confirm the bioactivity of 1–3 also indicated significant suppression of viral infection at concentrations of 2.8 µM for 1 and 10 µM for 2 and 3 (Figure 4). Although formoside (13) showed initial promise in reducing infection by SARS-CoV-2 in Calu-3 cells (Figure 3), these data were not replicated in a subsequent experiment (data not shown). Homofascaplysin A (1) exhibited promising inhibition of SARS-CoV-2 infection (EC\(_{50}\) 1.1 ± 0.4 µM) but suffered from relatively high cytotoxicity (CC\(_{50}\) ~5 µM) toward Calu-3 cells (Table 1). Following widely reported variability and cell-type dependencies for antiviral activities, the Calu-3 experiments were complemented with use of human primary airway cells in polarized pseudostratified air–liquid interface cultures. This model accurately recapitulates the biology of airway epithelia in vivo.\(^\text{41,42}\) At 2.8 µM, 1 effectively reduced viral load as indicated by the >90% reduction in harvested SARS-CoV-2 RNA compared with dimethyl sulfoxide (DMSO) control (Figure 5, A). Additionally, 1 did not affect adenoviral transduction, which was used as a toxicity control (Figure 5, B). However, compounds 2 and 3 were ineffective in this system at a test concentration of 10 µM.

![Figure 3](https://doi.org/10.1021/acs.jnatprod.2c00015)

**Figure 3.** Inhibition of SARS-CoV-2 infection by 10 natural products in human lung cancer Calu-3 cells. All compounds were prepared in 100% DMSO and used at a final concentration of 1 µM (1% DMSO) except for homofascaplysin A (1, 0.5 µM), cladophorol A (14, 10 µM), and cladophorol G (15, 10 µM). Following treatment with the compounds, cells were infected with SARS-CoV-2. After 48 h, cells were fixed and stained to visualize SARS-CoV-2-infected cells and nuclei. Both infected and uninfected cells were counted by automated microscopy; within each experiment, the number of total cells present at the end of the experiment was similar across all treatments (data not shown). 1% DMSO was used as vehicle control. The means of two independent experiments are shown with standard error of the mean.

![Figure 4](https://doi.org/10.1021/acs.jnatprod.2c00015)

**Figure 4.** Inhibition of SARS-CoV-2 infection in human lung cancer Calu-3 cells, performed as for Figure 3. Calu-3 cells were treated with the indicated compounds in a final concentration of 1% DMSO. Means of two independent experiments are shown with standard error of the mean.
While anti-SARS-CoV-2 inhibitory activities of 1−3 are less promising than known anti-SARS-CoV-2 natural products 4−8 (Figure 1, B), they are comparable to other anti-SARS-CoV-2 compounds that have recently been reported in the literature, albeit using different host cell systems.44−48 Homofascaplysin A (1), (+)-aureol (2), and bromophycolide A (3) represent three diverse structural classes of small molecules (β-carboline alkaloids, sesquiterpene hydroquinones, and meroditerpene macrolides, respectively) that offer numerous naturally occurring analogues and opportunities to create synthetic derivatives to pursue optimal antiviral and cytotoxicity profiles for development of lead candidates for treatment or prevention of SARS-CoV-2.35,49−56 As all of the studies were done with compound treatment of cells prior to infection, future work could address postinfection antiviral activity. Additionally, upcoming studies could utilize emerging tools such as replicons and virus-like particles to determine the antiviral mechanisms of lead candidates.57−61

The β-carboline alkaloid homofascaplysin A (1) belongs to the fascaplysin class of natural products, which display a range of biological activities.29,55 While fascaplysin has historically been known as a potent and selective CDK4 inhibitor, 1 and its congeners show potent antimicrobial, anticancer, and anti-Alzheimer’s activity.55,62−68 Fascaplysin has also been shown to be a “balanced” opioid receptor agonist with a signaling profile that resembles endorphins, in contrast to “biased” μ opioid receptor agonists such as morphine that participate in G protein signaling but weakly engage β-arrestin and endocytic machinery.59 Additionally, β-carboline alkaloids including harman (18), N-butyllharmine (19), harmol (20), and 9-N-methylharmine (21) have reported activity against HIV and dengue virus (Figure S2).30,51 Hence, the β-carboline alkaloids are an important family of molecules that have shown promise against a variety of disease targets.

Sesquiterpene hydroquinones as represented by (+)-aureol (2) are common among marine organisms. Several analogues of 2 have been isolated through our ICBG project from marine sponges and algae,70 with numerous natural and synthetic analogues described in the literature.33,34,71−74 (+)-Aureol (2) has been shown to exhibit anti-influenza activity in earlier studies.12 Analogues of 2 including stachyflin (16),13,34 strongylin A (22),69 and peyssonol A (23)75,76 possess antiviral activity and hence underscore the importance of exploring the sesquiterpene hydroquinone class of compounds for lead optimization against COVID-19. In vivo studies on structural analogues of 16 in mice and ferrets (for anti-influenza virus activity) indicate that the sesquiterpene hydroquinone class is indeed amenable to development as antiviral drug candidates.11

Macrocyclic terpenes as represented by bromophycolide A (3) are rare in nature, but Fijian red algae of the genus Callophycus are a renowned source of structurally complex diterpene-shikimate macrolides with variable halogenation, cyclization, and stereogenic motifs. Moreover, 3 is present at high concentrations in the producing alga, where it plays a role in defense against algal pathogens.35,78 Although there have been a few total synthesis efforts geared toward the meroditerpene macrolide core of bromophycolides, a concise total synthetic approach still remains at bay.79,80 Additionally, the biosynthetic pathways for 3 and naturally occurring analogues have not yet been deciphered. The bromophycolides display a range of
biological activities including antiviral (against HIV-1), antimicrobial (against meticillin-resistant *Staphylococcus aureus*, vancomycin-resistant *Enterococcus faecium*), antimalarial, and anticancer activities. While anti-HIV-1 activity of 3 is marginal (IC_{50} of 9.8 and 9.1 μM against HIV-1 strains 96U018PS7 and UG/92/029, respectively), 3 shows sub-micromolar blood stage antimalarial activity, targeting heme crystallization in the human malarial parasite *Plasmodium falciparum.*\(^{11,32}\) *In vivo* studies showed low toxicity and reasonable bioavailability in a malaria mouse model. However, the molecule suffers from rapid liver metabolism and hence a short *in vivo* half-life.\(^{31}\) Thus, future studies directed toward optimized analogues of 3 against SARS-CoV-2 can benefit from the pharmacokinetic and pharmacodynamic results reported for 3 in mouse models.

Taken together, the bioactivities observed for 1–3 encourage the exploration of compounds within their structural classes and can be envisioned to offer analogues exhibiting potent activity against SARS-CoV-2 via exploitable inhibitory mechanisms, while minimizing cytotoxicity. Whereas all current and future endeavors for antiviral drug discovery require a multifaceted approach, it is worth noting as stated by Dr. Francis S. Collins in a recent *Science* editorial that “Another lesson is that the necessary short-term dependence on repurposing existing drugs will not often produce true successful outcomes. For the future, we should begin to work on potent oral antivirals against all major classes of potential pathogens, with the goal of having drugs ready for phase 2/3 efficacy trials when the next threat emerges.”\(^{861}\)

## EXPERIMENTAL PROCEDURES

**General Experimental Procedures.** NMR spectral data were acquired on an 18.8 T (800 MHz for 1H and 201 MHz for 13C) Bruker Advance III HD instrument equipped with a 3 mm triple resonance cryoprobe. Spectra were recorded in DMSO-d_6, CDCl_3, and CD_3OD and referenced to the solvent residual peaks (δ_H and δ_C). NMR data were analyzed using MestReNova 11.0.4.

High-resolution MS data were acquired on a Thermo Scientific IDX Tridrib mass spectrometer. Low-resolution mass spectrometric data were acquired on a Waters Acquity QDa detector equipped with a Waters 2695 separation module. X-ray crystallographic data were acquired on an XtaLAB Synergy, Dualaxis, HyPix diffractometer. Optical rotation data were acquired in a Jasco-DIP-360 digital polarimeter.

**Specimen Collection and Species Identification.** *Fascaplysinopsis reticulata* (G-0633) was collected in 2008 from Thithia locale, Central Lau Island, Fiji (S 17°47’17.9”, W 179°23’52.8”) at a depth of 17 m. It had a conulose structure, medium hard texture with thin brown mucus and was dark brown in color. A collection photo for *Fascaplysinopsis reticulata* (G-0633) is provided in the Supporting Information (Figure S3). *Haliclona sp.* (G-1364) was collected in 2016 near Florida Island, Nggela Sule Island, Solomon Islands (S 9°03’05.8”, E 160°04’30.0”). The organism was found growing proli-ferously on a reef slope at a depth of 42 m. It had a soft texture and black color with a rope-like morphology. It had a black exudate. The sponge *Haliclona sp.* (G-1364) at a depth of 42 m. It had a soft texture and black color with a rope-like morphology. It had a black exudate.

**Isolation and Characterization of Natural Products.** Bromophycoclyde A (3),\(^{11,35}\) bromophycoclyde B (9),\(^{11,35}\) callophycolic acid B (10),\(^{11,35}\) peyssonneside A (12),\(^{11,35}\) formoside (13),\(^{11,35}\) cladophorol A (14), and cladophorol G (15)\(^{11,35}\) were isolated as part of previously published investigations of marine algal or sponges and characterized as detailed in earlier reports. All natural products were stored at −20 °C until used for the present study. The purity and identity of each compound were confirmed by comparison of 1H NMR spectroscopic data to original reports. Based on 1H NMR spectroscopic data (Figures S4–S6) bioactive compounds 1–3 were at least 90% pure. Compound quantities were determined using quantitative 1H NMR (qNMR) wherein the unknown quantity of a natural product was related to a known amount of caffeine (compound and caffeine were dissolved in equal volume of NMR solvent) using a capillary filled with benzene-d_6 as an internal standard.\(^{11,35}\)

*Isolation of Homofascaplysin A (1) and (+)-Aureol (2).* *Fascaplysinopsis reticulata* (1180 g) was exhaustively extracted with 50% aqueous methanol followed by methanol. The combined extracts were partially evaporated *in vacuo* and partitioned with dichloromethane. The dichloromethane extract was further partitioned with water. The dichloromethane soluble extract (3.2 g) was adsorbed on 200–350 mesh silica gel (1:10 loading capacity), in a flash benchtop open column, and eluted with a step gradient of hexanes/ethyl acetate (1:1) to ethyl acetate/methanol (1:1), furnishing six fractions. Fraction 1 (0.5 g) (pooled from 50% hexanes/ethyl acetate to ethyl acetate elutions) was flash chromatographed over 25 g of 200–350 mesh silica gel (gradient: hexanes to ethyl acetate). Further separation of the fraction containing 2 (as monitored with thin layer chromatography) by C18 silica flash benchtop open column chromatography (eluting with a gradient of 95% aqueous methanol to methanol) gave pure 2 as a yellow oil.

The remaining combined 50% aqueous methanol and methanol extract (after partitioning with dichloromethane) was adsorbed into HP20 SS resin, dried, and desalted with distilled water. Subsequent elution with methanol provided 1.1 g of extract, which was adsorbed onto 20.4 g of HP20 SS resin and eluted with a gradient of 20% aqueous methanol to 100% methanol followed with methanol.acetone (4:1) to 100% acetone to obtain eight fractions. The fraction eluting with 1:1 methanol/water furnished partially pure 1 (181.6 mg) as a red powder. A portion of this fraction (149.9 mg) was dissolved in chloroform and passed over Celite to furnish 2.4 mg of pure 1 as a brown solid.

Characterization data for 1 and 2 are reported in the Supporting Information.

*Haliconacyclamine A (11).* *Haliclona sp.* (750 g wet weight) was exhaustively extracted with methanol and then with dichloromethane. The crude extract (10.4 g) was suspended in a 9:1 mixture of methanol/water and partitioned with hexanes to furnish 1.9 g of hexanes-soluble fraction. The methanol/water extract was adjusted to 3:2 methanol/water and partitioned with dichloromethane to provide 2.6 g of dichloromethane-soluble extract. The methanol was evaporated, and the remaining water extract was partitioned with saturated butanol to give 1.5 g of butanol-soluble fraction. The dichloromethane-soluble fraction was subjected to silica gel column chromatography, eluting with hexanes and dichloromethane (0% to 100% dichloromethane step gradient), dichloromethane and ethyl acetate (0% to 100% ethyl acetate step gradient), ethyl acetate and methanol (0% to 100% methanol step gradient), and finally with methanol/water (1:1) with 0.1% trifluoroacetic acid (TFA) in the aqueous portion. The fraction eluting with 1:1 methanol/water gave 11 (1.1 g) as a white powder. Although the 1H and 13C NMR spectroscopic data for 11 did not entirely align with those reported in the literature for haliconacyclamine A,\(^{89}\) the structure was confirmed as haliconacyclamine A based on X-ray crystallographic data (Figure S11).\(^{89}\) The discrepancy in NMR data is likely due to protonation of the two nitrogen atoms present in 11 in our case.

**Viruses and Cells.** Vero E6 cells (#CRL-1586, ATCC, Manassas, VA, USA) are derived from the epithelium of an African green monkey kidney; they lack type I interferon production and are commonly used to grow virus stocks. Vero E6 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, #10313-021, Gibco, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS, #sh30396.03, lot# ag29759488, Crytiva, Marlborough, MA, USA), 2 mM L-glutamine (#25030-081, Gibco), 100 units/mL penicillin and 100 μg/mL streptomycin (#400-109, Gemini Bioproducts, West Sacramento, CA).
USA) at 37 °C in a humidified incubator supplemented with 5% CO₂. These cells have been used extensively in the lab, over 100 passages.

Calu-3 lung epithelial adenocarcinoma-derived cells (#HBT-SS, ATCC, Manassas, VA, USA) were cultured in Eagle’s minimal essential medium (#30-003, ATCC) supplemented with 10% FBS, 100 units/mL penicillin, and 100 μg/mL streptomycin at 37 °C in a humidified incubator supplemented with 5% CO₂. These cells were purchased for this study and were used in fewer than 20 passages.

Cryopreserved human bronchial epithelial cells (hBECs) from healthy donors (#FC0035, Lifeline Cell Technology, Frederick, MD, USA) were propagated in Ex Plus expansion medium (Stemcell Technologies, Cambridge, MA, USA) beginning at passage 3 on flasks coated with PureCol (Sigma-Aldrich, St. Louis, MO, USA) at 37 °C and 5% CO₂ until ~70–80% confluency. Monolayers were generated on collagen-coated (#234154, Sigma-Aldrich) 6.5 mm Transwells (#3470, Corning Life Sciences, Durham, NC, USA) by seeding at density of 150 000 cells per insert and maintained under submersed conditions in Ex Plus medium for 3 days. Apical and basolateral culture solutions were aspirated, and lower chamber fluid was replaced with ALI medium (Stemcell Technologies). Air–liquid interface conditions were maintained for 21–28 days until monolayers were fully differentiated.

SARS-CoV-2 isolate USA-WA1/2020 (BEI Resources, Manassas, VA, USA) was used in these studies. This represents an early isolate from the COVID-19 pandemic. To produce stocks, a confluent T75 flask of Vero E6 was infected with SARS-CoV-2 then monitored for cytopathic effect (cpe). When marked cpe was observed (typically 2–3 days postinfection), viral supernatant was collected, passed through a 0.22 μm filter to remove cell debris, aliquoted, and stored at −80 °C.

To determine the infectious titer of stocks, Vero E6 cells were seeded in 96-well plates at 20 000 cells per well; then, after 12–24 h they were infected with serially diluted SARS-CoV-2. After 4–8 h, cells were fixed in 4% paraformaldehyde in PBS, then stained with rabbit monoclonal anti-N (40143-R001, Sino Biologicals, VWR, Radnor, PA, USA) to identify infected cells and counter-stained with Hoechst-33342 to identify nuclei. Total cell number and infected cell number were determined by imaging with a Cytation 5 automated microscope (Biotek, Winooski, VT, USA) and image analysis using Gen5 Prime software (Biotek). The estimated titer was expressed as infectious units per mL.

**SARS-CoV-2 Antiviral Assays. Initial Screening and Dose—Response Assays.** Experiments were performed in 96-well plates. Calu3 cells were seeded at 30 000 cells per well. Cells were treated with compounds 24 h after seeding, at a confluency of 80–90%. They were infected at a low multiplicity of infection (MOI = 0.01) then incubated for 48 h before being fixed and stained for N protein. Total cell count was determined by counter-staining nuclei with Hoechst-33342. Nuclei and infected (N-protein positive) cells were counted using an automated microscope, as described above.

**Antiviral Activity in Primary Airways Cells.** Air–liquid interface cultures of hBECs were infected by the addition of 300 infectious units (determined on Vero E6) of SARS-CoV-2 in 10 μL of medium directly to the apical surface. RNA was harvested immediately (for a 0 h, input value) or after culturing for 48 h. Levels of the SARS-CoV-2 N protein RNA (a marker of viral replication) and the host transcription coding RNase P (an internal standard) were determined by reverse-transcription quantitative PCR (RT-qPCR). RNA was extracted using the PureLink RNA Mini kit (Thermo Fisher Scientific, Waltham, MA, USA) and eluted in a final volume of 100 μL of nuclelease-free water. Primers and probes were obtained as part of the SARS-CoV-2 Research Use Only qPCR primer & probe kit: N1, N2, and RP (IDT, Coralville, IA, USA). Reactions were prepared with the GoTaq Probe RT-qPCR system (#A6121, Promega, Madison, WI, USA) in a final volume of 10 μL, with 1 μL of extracted RNA, and run on a PicoReal 96 real-time PCR system (Thermo Fisher Scientific). A ΔΔCt method was used to determine effects on SARS-CoV-2 replication. The difference in cycle threshold (Ct) between N and RNase P was determined for each experimental condition, then compared to the difference observed at 0 h, i.e., before any replication can occur. Fold change is determined by assuming that a reduction in Ct of 1 cycle represents a 2-fold increase in the amount of starting RNA.

All experiments were performed with duplicate cultures and duplicate technical replicates for the RT-qPCR. Basic statistical analyses were performed using Microsoft Excel. Bioassay results were plotted using OriginPro software (OriginPro 2021, OriginLab Corporation, Northampton, MA, USA). EC₅₀ values were calculated using the Quest Graph IC₅₀ Calculator.

**ASSOCIATED CONTENT**

* Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jnatprod.2c00015.

Structures of natural products with promising antiviral activity including SARS-CoV, picture of *F. reticulata*, compound characterization data, ¹H NMR and HRMS spectra of bioactive/isolated compounds, and X-ray crystallographic data (PDF)

**AUTHOR INFORMATION**

Corresponding Author

Julia Kubanek — School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia 30332, United States; Center for Microbial Dynamics and Infection, School of Biological Sciences, and Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, Georgia 30322, United States

Philip R. Tedbury — Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia 30322, United States

Anne Marie Sweeney-Jones — School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia 30332, United States

Luke Mani — Institute of Applied Sciences, University of South Pacific, Suva, Fiji

Katy Soapi — Institute of Applied Sciences, University of South Pacific, Suva, Fiji

Candela Manfredi — Department of Pediatrics, Division of Pulmonary Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, United States

Eric Sorscher — Department of Pediatrics, Division of Pulmonary Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, United States

Stefan G. Saraños — Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia 30322, United States

Complete contact information is available at: https://pubs.acs.org/doi/10.1021/acs.jnatprod.2c00015

**Author Contributions**

* B.K.C. and P.R.T. contributed equally.

**Notes**

The authors declare no competing financial interest.

**ACKNOWLEDGMENTS**

This work was supported by ICBG grant U19-TW007401 from the NIH and The Nahmias-Schinazi Chair Fund at Emory
University, the governments of Solomon Islands and Fiji are thanked for allowing research and sample collection in their territorial waters. We are grateful to S. Lavoie (Université du Québec à Chicoutimi) for stimulating conversations leading us to this project. We thank J. Bacsó from the X-ray Crystallography Center at Emory University for the acquisition and interpretation of X-ray crystallographic data. S. G. Moore affiliated with the Institute of Bioengineering and Biosciences Systems Mass Spectrometry Core (SyMSC) at Georgia Tech shared expertise on the acquisition of high-resolution mass spectrometric data. L. Gelbaum and J. Leisen (Georgia Tech NMR Center) are acknowledged for NMR assistance. We thank K. Feusner (University of South Pacific) for taxonomic examination of collected sponges.

DEDICATION

Dedicated to Dr. William H. Gerwick, University of California at San Diego, for his pioneering work on bioactive natural products.

REFERENCES

(1) WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ (accessed 2022–03–07).
(2) FDA Press Announcements Page. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 (accessed 2021–11–04).
(3) FDA Press Announcements Page. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain (accessed 2021–12–26).
(4) Pfizer Press Release page. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-us-fda-emergency-use-authorization-novel (accessed 2021–12–26).
(5) FDA Press Announcements Page. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19 (accessed 2021–12–26).
(6) Hofmann, W. P.; Soriano, V.; van Elden, L. J.; van Loon, A. M.; van Alphen, F.; Hendriksen, K. Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection. In Handbook of Experimental Pharmacology: Antiviral Strategies; Krausslich, H. G.; Bartenschlager, R., Eds.; Springer: Berlin, Heidelberg, 2009; Vol. 189, pp 321–346.
(7) van Elden, L. J.; van Loon, A. M.; van Alphen, F.; Hendriksen, K. A.; Hoepelman, A. I.; van Kraaij, M. G.; Oosterheert, J. J.; Schipper, P.; Huang, S. H.; Lin, C. W. Biomolecules 2020, 10 (3), 366.
(8) Kim, D. W.; Seo, K. H.; Curtis-Long, M. J.; Oh, K. Y.; Oh, J. W.; Cho, J. K.; Lee, K. H.; Park, K. H. J. Enzyme Inhib. Med. Chem. 2014, 29 (1), 59–63.
(9) Cho, J. K.; Curtis-Long, M. J.; Lee, K. H.; Kim, D. W.; Ryu, H. W.; Yue, H. J.; Park, K. H. Bioorg. Med. Chem. 2013, 21 (11), 3051–3057.
(10) Park, J. Y.; Kim, J. H.; Kim, Y. M.; Jeong, H. J.; Kim, D. W.; Park, K. H.; Kwon, H. J.; Park, S. J.; Lee, W. S.; Ryu, Y. B. Bioorg. Med. Chem. 2012, 20 (19), 5928–5935.
(11) Park, J. Y.; Yue, H. J.; Ryu, H. W.; Lin, S. H.; Kim, K. S.; Park, K. H.; Ryu, Y. B.; Lee, W. S. J. Enzyme Inhib. Med. Chem. 2017, 32 (1), 504–515.
(12) Sayed, A. M.; Khattab, A. R.; AboulMagd, A. M.; Hassan, H. M.; El Sayed, K. A. Natural Products as Antiviral Agents. In Handbook of Experimenta/ Biden, T.; Atta-ur-Rahman, Ed.; Elsevier, 2000; Vol. 63.
(13) Gogineni, V.; Schinazi, R. F.; Hamann, M. T. Chem. Res. 2015, 48 (1), 562–567.
(14) Islam, M. T.; Sarkar, C.; El-Kersh, D. M.; Jamaddar, S.; Uddin, S. J.; Shalpi, J. A.; Mubarak, M. S. Phytother. Res. 2020, 34 (10), 2471–2492.
(15) Christy, M. P.; Uekusa, Y.; Gerwick, L. G.; Gerwick, W. H. J. Nat. Prod. 2022, 85 (4), 1261–1270.
(16) Xie, X.; Lu, S.; Pan, X.; Zou, M.; Li, F.; Lin, H.; Hu, J.; Fan, S.; He, J. J. Nat. Prod. 2021, 84 (2), 537–543.
(17) Ashhurst, A. S.; Tang, A. H.; Fajtová, P.; Yoon, M. C.; Aggarwal, A.; Bedding, M. J.; Stoye, A.; Beretta, L.; Phee, D.; Drelich, A.; Skinner, D.; Li, M.; Meek, T. D.; McKerrow, J. H.; Hook, V.; Tseng, C. T.; Larance, M.; Turville, S.; Gerwick, W. H.; O’Donoghue, A. J.; Payne, R. J. Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L. J. Med. Chem. 2022, 65, 2956.
(18) Li, Y. T.; Yang, C.; Wu, Y.; Liu, J. J.; Feng, X.; Tian, X.; Zhou, Z.; Pan, X.; Liu, S.; Tian, L. J. Nat. Prod. 2021, 84 (2), 436–443.
(19) White, K. M.; Rosales, R.; Yildiz, S.; Khehr, T.; Moreino, L.; Moreno, E.; Angara, S.; Uccellini, M. B.; Rathnasinghe, R.; Coughlan, L.; Garcia-Sastre, A. Science 2021, 371 (6532), 926–931.
(20) Kirsch, G.; Gong, C. M.; Wright, A. D.; Kaminsky, R. J. Nat. Prod. 2000, 63 (6), 825–829.
(21) Ishida, J.; Wang, H. K.; Oyama, M.; Coşentino, M. L.; Hu, C. Q.; Lee, K. H. J. Nat. Prod. 2001, 64 (7), 958–960.
(22) Quintana, V. M.; Piccini, L. E.; Panozzo Zénere, J. D.; Damonte, E. B.; Ponce, M. A.; Castilla, V. Antivir. Res. 2016, 134, 26–33.
(23) Wright, A. E.; Cross, S. S.; Burres, N.; Koehn, P. Novel antiviral and antitumor terpene hydroquinones and methods of use. US patent 2005, 5,519, 1991.
(24) Kubanek, J.; Prusak, A. C.; Snell, T. W.; Hay, M. E.; Kamisky, R. J. Org. Chem. 2012, 77 (18), 8000–8006.
(25) Kubanek, J.; Prusak, A. C.; Hardcastle, K. I.; Fairchild, C. R.; Aalbersberg, W.; Raventos-Suarez, C.; Hay, M. E. Callophycus serratus. J. Org. Chem. 2007, 72 (13), 7343–7351.
(26) Teasdale, M. E.; Shearer, T. L.; Engel, S.; Alexander, T. S.; Fairchild, C. R.; Prudhomme, J.; Torres, M.; Le Roch, K.; Aalbersberg, W.; Hay, M. E.; Kubanek, J. J. Org. Chem. 2012, 77 (18), 8000–8006.
(27) Lane, A. L.; Stott, E. P.; Hay, M. E.; Prusak, A. C.; Hardcastle, K.; Fairchild, C. R.; Franzblau, S. G.; Le Roch, K.; Prudhomme, J.; Aalbersberg, W.; Kubanek, J. Callophycus serratus. J. Org. Chem. 2007, 72 (19), 7343–7351.
(28) Tietjen, I.; Williams, D. E.; Read, S.; Kuang, X. T.; Mwimani, P.; Wilhelm, E.; Markle, T.; Kinloch, N. N.; Naphen, C. N.; Tenney, K.;
(87) Lavoie, S.; Sweeney-Jones, A. M.; Mojib, N.; Dale, B.; Gagaring, K.; McNamara, C. W.; Quave, C. L.; Soapi, K.; Kubanek, J. Cladophora socialis. J. Org. Chem. 2019, 84 (9), 5035−5045.

(88) Bharti, S. K.; Roy, R. Trends Anal. Chem. 2012, 35, 5−26.

(89) Clark, R. J.; Field, K. L.; Charan, R. D.; Garson, M. J.; Brereton, M.; Willis, A. C. Tetrahedron 1998, 54 (30), 8811−8826.

(90) Mudianta, I. W.; Garson, M. J.; Bernhardt, P. V. Aust. J. Chem. 2009, 62 (7), 667−670.

(91) Quest Graph IC$_{50}$ Calculator. AAT Bioquest, Inc., https://www.aatbio.com/tools/ic50-calculator, Aug. 2021.